BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11728232)

  • 1. Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?
    Bruserud Ø; Wendelboe Ø
    Expert Opin Biol Ther; 2001 Nov; 1(6):1005-16. PubMed ID: 11728232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.
    Wendelbo Ø; Nesthus I; Sjo M; Paulsen K; Ernst P; Bruserud Ø
    Cancer Immunol Immunother; 2004 Aug; 53(8):740-7. PubMed ID: 15133630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients' Response to Immunotherapy.
    Fischbacher D; Merle M; Liepert A; Grabrucker C; Kroell T; Kremser A; Dreyßig J; Freudenreich M; Schuster F; Borkhardt A; Kraemer D; Koehne CH; Kolb HJ; Schmid C; Schmetzer HM
    Cell Commun Adhes; 2015; 22(2-6):49-65. PubMed ID: 27602789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation.
    Bruserud O; Ulvestad E; Berentsen S; Bergheim J; Nesthus I
    Scand J Immunol; 1998 Jan; 47(1):54-62. PubMed ID: 9467659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in the treatment of acute myelogenous leukemia (AML): rationale, results and future prospects.
    Urbanitz D; Büchner T; Pielken H; van de Loo J
    Klin Wochenschr; 1983 Oct; 61(19):947-54. PubMed ID: 6196515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of gamma-irradiation on acute myelogenous leukemia blasts: in vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation.
    Bruserud O; Ulvestad E
    J Hematother Stem Cell Res; 1999 Aug; 8(4):431-41. PubMed ID: 10634181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.
    Orleans-Lindsay JK; Barber LD; Prentice HG; Lowdell MW
    Clin Exp Immunol; 2001 Dec; 126(3):403-11. PubMed ID: 11737054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies.
    Bruserud O
    Leukemia; 1999 Aug; 13(8):1175-87. PubMed ID: 10450745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia.
    Bruserud O; Ulvestad E
    J Interferon Cytokine Res; 2000 Nov; 20(11):947-54. PubMed ID: 11096451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
    Steger B; Milosevic S; Doessinger G; Reuther S; Liepert A; Braeu M; Schick J; Vogt V; Schuster F; Kroell T; Busch DH; Borkhardt A; Kolb HJ; Tischer J; Buhmann R; Schmetzer H
    Immunobiology; 2014 Apr; 219(4):247-60. PubMed ID: 24315637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
    Bruserud O; Ulvestad E
    Cancer Immunol Immunother; 2000 Sep; 49(7):377-87. PubMed ID: 10999464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histamine and interleukin-2 in acute myelogenous leukemia.
    Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
    Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
    Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
    Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells.
    Bruserud O
    Cancer Immunol Immunother; 1998 Jun; 46(4):221-8. PubMed ID: 9671145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-13 secretion by normal and posttransplant T lymphocytes; in vitro studies of cellular immune responses in the presence of acute leukaemia blast cells.
    Bruserud O; Pawelec G
    Cancer Immunol Immunother; 1997 Oct; 45(1):45-52. PubMed ID: 9353426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of cytotoxic lymphocyte subsets against leukemia by stimulation with AML blasts.
    Lotzová E; Savary CA
    Med Oncol Tumor Pharmacother; 1993; 10(1-2):13-9. PubMed ID: 8258990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy prospects for acute myeloid leukaemia.
    Barrett AJ; Le Blanc K
    Clin Exp Immunol; 2010 Aug; 161(2):223-32. PubMed ID: 20529084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
    Nahas MR; Stroopinsky D; Rosenblatt J; Cole L; Pyzer AR; Anastasiadou E; Sergeeva A; Ephraim A; Washington A; Orr S; McMasters M; Weinstock M; Jain S; Leaf RK; Ghiasuddin H; Rahimian M; Liegel J; Molldrem JJ; Slack F; Kufe D; Avigan D
    Br J Haematol; 2019 May; 185(4):679-690. PubMed ID: 30828801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-mediated cytotoxicity as a result of immunotherapy in patients with acute myeloid leukaemia.
    Taylor GM; Harris R; Freeman CB
    Br J Cancer; 1976 Feb; 33(2):137-43. PubMed ID: 1063029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-7 (IL-7) in patients receiving intensive chemotherapy for acute myelogenous leukemia: studies of systemic IL-7 Levels and IL-7 responsiveness of circulating T lymphocytes.
    Wendelbo Ø; Glenjen N; Bruserud Ø
    J Interferon Cytokine Res; 2002 Oct; 22(10):1057-65. PubMed ID: 12433286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.